Eli Lilly chief scientific and product officer Daniel Skovronsky discusses FDA approval of its new oral GLP-1 drug, a $4.5B...
Global trade, energy transition, financial regulation, multinational corporations, and macroeconomic trends.
Categories
Recent Posts
- 132-year-old luxury chain quietly closes more stores worldwide
- Positive move: Moody’s ‘upgrades’ South Africa’s outlook
- Tech billionaires convinced Trump to back off AI executive order
- Bank of America resets Google stock forecast after key event
- Whole Foods minestrone soup recalled in 17 states over undeclared shrimp